TAME study
An upcoming study that will attempt to answer the question of Metformin's geroprotective effects in humans by studying disease onset in susceptible but otherwise healthy individuals.
Videos Mentioning TAME study
#123–Joan Mannick & Nir Barzilai: Rapamycin and metformin—longevity, immune enhancement, & COVID-19
Peter Attia MD
A phase 3 clinical trial led by Nir Barzilai, aiming to prove that Metformin can prevent age-related diseases and extend healthy lifespan, with a budget of 78 million dollars and 3,000 subjects.
#103 – Looking back on the first 99 episodes: Strong Convictions, Loosely Held
Peter Attia MD
A study discussed in relation to Metformin's potential to extend life by delaying the onset of chronic disease, particularly in individuals without diabetes.
204 - Centenarians, metformin, and longevity | Nir Barzilai, M.D.
Peter Attia MD
A groundbreaking clinical trial designed to test metformin's efficacy as a geroprotective agent in non-diabetic elderly individuals, with a primary outcome focused on a cluster of age-related diseases and mortality.
300-Special episode: Peter on exercise, fasting, nutrition, stem cells, geroprotective drugs, & more
Peter Attia MD
An upcoming study that will attempt to answer the question of Metformin's geroprotective effects in humans by studying disease onset in susceptible but otherwise healthy individuals.